Mixtard 30 Penfill (Insulin Human)

Insulin human, the active ingredient in Mixtard 30 Penfill, is an insulin presented as a solution for injection, prefilled pen for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients by providing basal and prandial insulin coverage.

GNH USA supplies Mixtard 30 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mixtard 30 Penfill is a human insulin used in the management of diabetes mellitus, providing both basal and mealtime glucose control.

- Type 1 diabetes mellitus: improves overall glycemic control by replacing deficient endogenous insulin. - Type 2 diabetes mellitus: assists in achieving target blood glucose when oral agents are insufficient. - Diabetes mellitus (any type): offers combined basal and rapid‑acting insulin action for flexible dosing.

Mixtard 30 Penfill may be associated with a range of adverse reactions.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increased caloric storage due to improved glucose utilization. - Lipodystrophy: localized fat accumulation or loss at injection sites. - Edema: mild peripheral swelling. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological impairment requiring immediate assistance. - Allergic reaction or anaphylaxis: rash, itching, swelling, or difficulty breathing. - Insulin antibodies: may alter insulin effectiveness. - Diabetic ketoacidosis: rare if insulin dose is insufficient or abruptly stopped.

When using Mixtard 30 Penfill, several safety considerations should be observed.

- Blood glucose monitoring: check levels regularly to adjust dose as needed. - Hypoglycemia risk: avoid dosing when blood glucose is already low. - Illness or stress: may require temporary dose adjustments. - Renal or hepatic impairment: use with caution and monitor glucose closely. - Pregnancy and lactation: safety not fully established; consult a healthcare professional. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin may interact with other medicines, altering its glucose‑lowering effect.

Major Interactions (Avoid): - Beta‑blockers: can mask symptoms of hypoglycemia. - Sulfonylureas and meglitinides: increase risk of severe hypoglycemia. - ACE inhibitors: may potentiate insulin’s glucose‑lowering action.

Moderate Interactions (Monitor Closely): - Corticosteroids: raise blood glucose, possibly requiring higher insulin doses. - Thiazide diuretics: may increase glucose levels. - Oral contraceptives: can affect insulin sensitivity and glucose control.